Donepezil-Hcl 1 A Pharma (Donepezil Hydrochloride)

Donepezil-HCl 1 A Pharma is prescribed primarily for the symptomatic treatment of Alzheimer’s disease in its mild to moderate stages. Clinical use focuses on improving cognition, memory, and daily functioning in affected individuals.

• Management of mild to moderate Alzheimer’s disease symptoms
• Adjunct therapy to support cognitive performance
• Use in patients with documented cholinergic deficits
• Consideration for patients who have not responded to non‑pharmacologic interventions
• Integration into a comprehensive dementia care plan

Side effects of donepezil may vary in frequency and severity. Patients should be aware of both common and less frequent serious reactions.

Common

• Nausea or upset stomach
• Diarrhea or loose stools
• Insomnia or vivid dreams
• Muscle cramps or fatigue
• Headache
• Dizziness

Serious

• Bradycardia or heart block
• Severe gastrointestinal bleeding
• Hepatotoxicity with elevated liver enzymes
• Seizures or convulsions
• Allergic reactions such as rash or angioedema
• Persistent vomiting leading to dehydration

Before initiating Donepezil-HCl 1 A Pharma, clinicians should evaluate patient history and monitor for potential risks.

• Assess cardiac function, especially in patients with arrhythmias
• Review liver function tests prior to treatment
• Caution in patients with a history of peptic ulcer disease or gastrointestinal bleeding
• Monitor for signs of severe weight loss or malnutrition
• Evaluate for concurrent use of other cholinergic agents
• Discuss pregnancy and lactation status, as safety data are limited

Donepezil can interact with several medications, requiring careful review of a patient’s medication list.

Avoid

• Anticholinergic drugs such as atropine or scopolamine
• Non‑selective beta‑blockers that may exacerbate bradycardia
• Strong CYP3A4 inhibitors (e.g., ketoconazole, clarithromycin)
• Drugs that prolong the QT interval

Use with caution

• Other acetylcholinesterase inhibitors
• NSAIDs or aspirin in patients at risk for GI bleeding
• Antidepressants that affect serotonin levels
• Medications affecting hepatic metabolism (e.g., rifampin)